
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington -Allergic contact dermatitis (ACD) has an appreciable, detrimental effect on quality of life, according to the results of a survey presented by Donald V. Belsito, M.D., at the annual meeting of the American Academy of Dermatology.